Cargando…

Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells

The microtubule-targeting agents (MTAs) are well-known chemotherapeutic agents commonly used for therapy of a broad spectrum of human malignancies, exhibiting epithelial origin, including breast, lung, and prostate cancer. Despite the impressive response rates shortly after initiation of MTA-based t...

Descripción completa

Detalles Bibliográficos
Autores principales: Boichuk, Sergei, Dunaev, Pavel, Mustafin, Ilshat, Mani, Shinjit, Syuzov, Kirill, Valeeva, Elena, Bikinieva, Firuza, Galembikova, Aigul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945560/
https://www.ncbi.nlm.nih.gov/pubmed/35327403
http://dx.doi.org/10.3390/biomedicines10030601
_version_ 1784673987973873664
author Boichuk, Sergei
Dunaev, Pavel
Mustafin, Ilshat
Mani, Shinjit
Syuzov, Kirill
Valeeva, Elena
Bikinieva, Firuza
Galembikova, Aigul
author_facet Boichuk, Sergei
Dunaev, Pavel
Mustafin, Ilshat
Mani, Shinjit
Syuzov, Kirill
Valeeva, Elena
Bikinieva, Firuza
Galembikova, Aigul
author_sort Boichuk, Sergei
collection PubMed
description The microtubule-targeting agents (MTAs) are well-known chemotherapeutic agents commonly used for therapy of a broad spectrum of human malignancies, exhibiting epithelial origin, including breast, lung, and prostate cancer. Despite the impressive response rates shortly after initiation of MTA-based therapy, the vast majority of human malignancies develop resistance to MTAs due to the different mechanisms. Here, we report that infigratinib (BGJ 398), a potent FGFR1-4 inhibitor, restores sensitivity of a broad spectrum of ABCB1-overexpressing cancer cells to certain chemotherapeutic agents, including paclitaxel (PTX) and doxorubicin (Dox). This was evidenced for the triple-negative breast cancer (TNBC), and gastrointestinal stromal tumor (GIST) cell lines, as well. Indeed, when MDR-overexpressing cancer cells were treated with a combination of BGJ 398 and PTX (or Dox), we observed a significant increase of apoptosis which was evidenced by an increased expression of cleaved forms of PARP, caspase-3, and increased numbers of Annexin V-positive cells, as well. Moreover, BGJ 398 used in combination with PTX significantly decreased the viability and proliferation of the resistant cancer cells. As expected, no apoptosis was found in ABCB1-overexpressing cancer cells treated with PTX, Dox, or BGJ 398 alone. Inhibition of FGFR-signaling by BGJ 398 was evidenced by the decreased expression of phosphorylated (i.e., activated) forms of FGFR and FRS-2, a well-known adaptor protein of FGFR signaling, and downstream signaling molecules (e.g., STAT-1, -3, and S6). In contrast, expression of MDR-related ABC-transporters did not change after BGJ 398 treatment, thereby suggesting an impaired function of MDR-related ABC-transporters. By using the fluorescent-labeled chemotherapeutic agent PTX-Alexa488 (Flutax-2) and doxorubicin, exhibiting an intrinsic fluorescence, we found that BGJ 398 substantially impairs their efflux from MDR-overexpressing TNBC cells. Moreover, the efflux of Calcein AM, a well-known substrate for ABCB1, was also significantly impaired in BGJ 398-treated cancer cells, thereby suggesting the ABCB1 as a novel molecular target for BGJ 398. Of note, PD 173074, a potent FGFR1 and VEGFR2 inhibitor failed to retain chemotherapeutic agents inside ABCB1-overexpressing cells. This was consistent with the inability of PD 173074 to sensitize Tx-R cancer cells to PTX and Dox. Collectively, we show here for the first time that BGJ 398 reverses the sensitivity of MDR-overexpressing cancer cells to certain chemotherapeutic agents due to inhibition of their efflux from cancer cells via ABCB1-mediated mechanism.
format Online
Article
Text
id pubmed-8945560
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89455602022-03-25 Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells Boichuk, Sergei Dunaev, Pavel Mustafin, Ilshat Mani, Shinjit Syuzov, Kirill Valeeva, Elena Bikinieva, Firuza Galembikova, Aigul Biomedicines Article The microtubule-targeting agents (MTAs) are well-known chemotherapeutic agents commonly used for therapy of a broad spectrum of human malignancies, exhibiting epithelial origin, including breast, lung, and prostate cancer. Despite the impressive response rates shortly after initiation of MTA-based therapy, the vast majority of human malignancies develop resistance to MTAs due to the different mechanisms. Here, we report that infigratinib (BGJ 398), a potent FGFR1-4 inhibitor, restores sensitivity of a broad spectrum of ABCB1-overexpressing cancer cells to certain chemotherapeutic agents, including paclitaxel (PTX) and doxorubicin (Dox). This was evidenced for the triple-negative breast cancer (TNBC), and gastrointestinal stromal tumor (GIST) cell lines, as well. Indeed, when MDR-overexpressing cancer cells were treated with a combination of BGJ 398 and PTX (or Dox), we observed a significant increase of apoptosis which was evidenced by an increased expression of cleaved forms of PARP, caspase-3, and increased numbers of Annexin V-positive cells, as well. Moreover, BGJ 398 used in combination with PTX significantly decreased the viability and proliferation of the resistant cancer cells. As expected, no apoptosis was found in ABCB1-overexpressing cancer cells treated with PTX, Dox, or BGJ 398 alone. Inhibition of FGFR-signaling by BGJ 398 was evidenced by the decreased expression of phosphorylated (i.e., activated) forms of FGFR and FRS-2, a well-known adaptor protein of FGFR signaling, and downstream signaling molecules (e.g., STAT-1, -3, and S6). In contrast, expression of MDR-related ABC-transporters did not change after BGJ 398 treatment, thereby suggesting an impaired function of MDR-related ABC-transporters. By using the fluorescent-labeled chemotherapeutic agent PTX-Alexa488 (Flutax-2) and doxorubicin, exhibiting an intrinsic fluorescence, we found that BGJ 398 substantially impairs their efflux from MDR-overexpressing TNBC cells. Moreover, the efflux of Calcein AM, a well-known substrate for ABCB1, was also significantly impaired in BGJ 398-treated cancer cells, thereby suggesting the ABCB1 as a novel molecular target for BGJ 398. Of note, PD 173074, a potent FGFR1 and VEGFR2 inhibitor failed to retain chemotherapeutic agents inside ABCB1-overexpressing cells. This was consistent with the inability of PD 173074 to sensitize Tx-R cancer cells to PTX and Dox. Collectively, we show here for the first time that BGJ 398 reverses the sensitivity of MDR-overexpressing cancer cells to certain chemotherapeutic agents due to inhibition of their efflux from cancer cells via ABCB1-mediated mechanism. MDPI 2022-03-03 /pmc/articles/PMC8945560/ /pubmed/35327403 http://dx.doi.org/10.3390/biomedicines10030601 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Boichuk, Sergei
Dunaev, Pavel
Mustafin, Ilshat
Mani, Shinjit
Syuzov, Kirill
Valeeva, Elena
Bikinieva, Firuza
Galembikova, Aigul
Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells
title Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells
title_full Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells
title_fullStr Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells
title_full_unstemmed Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells
title_short Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells
title_sort infigratinib (bgj 398), a pan-fgfr inhibitor, targets p-glycoprotein and increases chemotherapeutic-induced mortality of multidrug-resistant tumor cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945560/
https://www.ncbi.nlm.nih.gov/pubmed/35327403
http://dx.doi.org/10.3390/biomedicines10030601
work_keys_str_mv AT boichuksergei infigratinibbgj398apanfgfrinhibitortargetspglycoproteinandincreaseschemotherapeuticinducedmortalityofmultidrugresistanttumorcells
AT dunaevpavel infigratinibbgj398apanfgfrinhibitortargetspglycoproteinandincreaseschemotherapeuticinducedmortalityofmultidrugresistanttumorcells
AT mustafinilshat infigratinibbgj398apanfgfrinhibitortargetspglycoproteinandincreaseschemotherapeuticinducedmortalityofmultidrugresistanttumorcells
AT manishinjit infigratinibbgj398apanfgfrinhibitortargetspglycoproteinandincreaseschemotherapeuticinducedmortalityofmultidrugresistanttumorcells
AT syuzovkirill infigratinibbgj398apanfgfrinhibitortargetspglycoproteinandincreaseschemotherapeuticinducedmortalityofmultidrugresistanttumorcells
AT valeevaelena infigratinibbgj398apanfgfrinhibitortargetspglycoproteinandincreaseschemotherapeuticinducedmortalityofmultidrugresistanttumorcells
AT bikinievafiruza infigratinibbgj398apanfgfrinhibitortargetspglycoproteinandincreaseschemotherapeuticinducedmortalityofmultidrugresistanttumorcells
AT galembikovaaigul infigratinibbgj398apanfgfrinhibitortargetspglycoproteinandincreaseschemotherapeuticinducedmortalityofmultidrugresistanttumorcells